Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 6.1% – Time to Sell?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) fell 6.1% during trading on Tuesday . The company traded as low as $26.17 and last traded at $25.71. 75,375 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 522,388 shares. The stock had previously closed at $27.37.

Analyst Upgrades and Downgrades

KYMR has been the topic of a number of research reports. Citigroup began coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective on the stock. Stephens restated an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. BTIG Research began coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 target price on the stock. HC Wainwright increased their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Leerink Partners reissued an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Kymera Therapeutics Stock Down 7.2 %

The firm’s 50-day moving average is $35.60 and its 200-day moving average is $41.63. The company has a market capitalization of $1.65 billion, a PE ratio of -10.88 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 2,241 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the sale, the insider now directly owns 80,085 shares of the company’s stock, valued at $2,438,588.25. This trade represents a 2.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,788 shares of company stock worth $455,202 in the last ninety days. 15.82% of the stock is owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its stake in shares of Kymera Therapeutics by 12.6% in the 4th quarter. California State Teachers Retirement System now owns 36,839 shares of the company’s stock worth $1,482,000 after buying an additional 4,131 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Kymera Therapeutics during the fourth quarter valued at approximately $4,610,000. GF Fund Management CO. LTD. bought a new position in shares of Kymera Therapeutics during the 4th quarter valued at $55,000. Woodline Partners LP boosted its position in Kymera Therapeutics by 2.3% in the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company’s stock worth $21,621,000 after purchasing an additional 12,334 shares during the last quarter. Finally, Vident Advisory LLC purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth approximately $236,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.